HK1020756A1 - Use of angiogenic factor vegf145 in treating cardiovascular disease - Google Patents
Use of angiogenic factor vegf145 in treating cardiovascular diseaseInfo
- Publication number
- HK1020756A1 HK1020756A1 HK99105958A HK99105958A HK1020756A1 HK 1020756 A1 HK1020756 A1 HK 1020756A1 HK 99105958 A HK99105958 A HK 99105958A HK 99105958 A HK99105958 A HK 99105958A HK 1020756 A1 HK1020756 A1 HK 1020756A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vegf145
- derivatives
- novel
- protein products
- vegf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2553796P | 1996-09-06 | 1996-09-06 | |
US08/784,551 US6013780A (en) | 1996-09-06 | 1997-01-21 | VEGF145 expression vectors |
PCT/US1997/015471 WO1998010071A1 (fr) | 1996-09-06 | 1997-09-04 | Facteur angiogenique et utilisation de celui-ci dans le traitement de maladies cardiovasculaires |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1020756A1 true HK1020756A1 (en) | 2000-05-19 |
Family
ID=26699889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK99105958A HK1020756A1 (en) | 1996-09-06 | 1999-12-17 | Use of angiogenic factor vegf145 in treating cardiovascular disease |
Country Status (15)
Country | Link |
---|---|
US (3) | US6013780A (fr) |
EP (1) | EP0925360B1 (fr) |
JP (1) | JP2001500728A (fr) |
KR (1) | KR20000068506A (fr) |
CN (1) | CN1236390A (fr) |
AT (1) | ATE256186T1 (fr) |
AU (1) | AU737898B2 (fr) |
CA (1) | CA2265252C (fr) |
DE (1) | DE69726741T2 (fr) |
EA (1) | EA004646B1 (fr) |
ES (1) | ES2212127T3 (fr) |
HK (1) | HK1020756A1 (fr) |
IL (1) | IL128727A (fr) |
NZ (1) | NZ334508A (fr) |
WO (1) | WO1998010071A1 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238673B2 (en) | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US20040071637A1 (en) * | 1993-04-27 | 2004-04-15 | Elia James P. | Method for repairing a damaged portion of a human organ |
US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
US20030165467A1 (en) * | 1997-01-21 | 2003-09-04 | Technion Research & Development Co., Ltd. | Angiogenic factor and use thereof in treating cardiovascular disease |
US6485942B1 (en) | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
NZ505955A (en) * | 1998-02-06 | 2005-04-29 | Collateral Therapeutics Inc | Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF-A, and pharmaceutical use |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
CA2340593C (fr) * | 1998-10-26 | 2012-05-08 | Kari Alitalo | Utilisation du gene ou de la proteine vegf-c ou vegf-d pour prevenir la restenose |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US20040131601A1 (en) * | 2000-03-30 | 2004-07-08 | Foundry Networks, Inc., A Delaward Corporation | Injection of bone marrow-derived cells and medium for angiogenesis |
US7097832B1 (en) * | 1999-03-30 | 2006-08-29 | Myocardial Therapeutics, Inc. | Intramyocardial injection of autologous bone marrow |
US7125856B1 (en) | 1999-04-15 | 2006-10-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
AU5023300A (en) | 1999-05-20 | 2000-12-12 | Scios Inc. | Vascular endothelial growth factor variants |
EP1183357A2 (fr) * | 1999-05-20 | 2002-03-06 | Scios Inc. | Dimeres, facteurs de croissance de l'endothelium vasculaire |
US6899731B2 (en) * | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US7037332B2 (en) * | 2000-03-15 | 2006-05-02 | Orbus Medical Technologies, Inc. | Medical device with coating that promotes endothelial cell adherence |
US8460367B2 (en) | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
CA2404616C (fr) | 2000-04-12 | 2009-08-18 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Utilisation de vegf et d'homologues pour traiter des troubles du neurone |
WO2002002148A2 (fr) * | 2000-06-30 | 2002-01-10 | Collateral Therapeutics, Inc. | Compositions de therapie genique renfermant deux genes recombines, et methodes d'utilisation correspondantes |
CA2419245A1 (fr) * | 2000-08-17 | 2002-02-21 | Keiya Ozawa | Distribution de facteurs angiogeniques a mediation assuree par virus associe aux adenovirus |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6953560B1 (en) | 2000-09-28 | 2005-10-11 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US7026462B2 (en) | 2000-12-07 | 2006-04-11 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US6663662B2 (en) * | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US20050142130A1 (en) * | 2001-01-04 | 2005-06-30 | Roks Antonius J.M. | Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima |
EP1399484B1 (fr) * | 2001-06-28 | 2010-08-11 | Domantis Limited | Ligand a double specificite et son utilisation |
WO2004003019A2 (fr) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Ligand |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
NZ543755A (en) | 2001-08-29 | 2008-04-30 | Genentech Inc | Bv8 nucleic acids and polypeptides with mitogenic activity |
JP2005502672A (ja) | 2001-08-29 | 2005-01-27 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | サイモシンβ4、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法 |
US6753071B1 (en) * | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
AU2003232152A1 (en) * | 2002-05-30 | 2003-12-19 | Myocardial Therapeutics, Inc. | Intramyocardial injection of autologous bone marrow |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
CN100398652C (zh) * | 2002-12-09 | 2008-07-02 | 图尔金株式会社 | 调节性锌指蛋白 |
WO2004055156A2 (fr) * | 2002-12-17 | 2004-07-01 | Technion Research And Development Foundation Ltd. | Variante de facteur de croissance endotheliale vasculaire (vegf) manquant d'activite de liaison du vegfr-1 et son utilisation dans l'activation de l'endothelisation et la prevention de la restenose intra-stent |
JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
EP1615659B1 (fr) | 2003-03-12 | 2014-04-16 | Genentech, Inc. | Utilisation de bv8 et/ou de eg-vegf pour promouvoir l'hématopoièse |
BRPI0610499A2 (pt) * | 2005-04-12 | 2010-06-22 | Intradigm Corp | moléculas de ácido nucléico , composições e usos das referidas moléculas |
US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
KR100772424B1 (ko) * | 2005-08-05 | 2007-11-01 | 박기랑 | ⅤEGF-A,ⅤEGF-B,및 ⅤEGF-C의 안티센스 cDNA를 함유하는 재조합 아데노-연관 바이러스 및 ⅤEGFR 트렁케이티드 솔루블 cDNA를 함유하는 재조합 아데노-연관 바이러스를 포함하는 암의 유전자 치료제 |
EP1957536A2 (fr) * | 2005-12-01 | 2008-08-20 | Domantis Limited | Formats d'anticorps a domaine non competitif qui lient le recepteur type 1 d'interleukine 1 |
MX2009012968A (es) * | 2007-06-06 | 2010-04-01 | Domantis Ltd | Polipeptidos, dominios variables de anticuerpo y antagonistas. |
ES2440751T3 (es) * | 2008-10-07 | 2014-01-30 | Boston Scientific Scimed, Inc. | Dispositivos médicos para administración de agentes terapéuticos a los lúmenes corporales |
CN110760542B (zh) * | 2019-11-18 | 2022-07-26 | 天津大学 | 一种共表达znf580和vegf165双基因的质粒及应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240848A (en) * | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5288846A (en) * | 1990-10-19 | 1994-02-22 | The General Hospital Corporation | Cell specific gene regulators |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
US5792636A (en) * | 1994-07-20 | 1998-08-11 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing a stable carboxylesterase in dry form |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
-
1997
- 1997-01-21 US US08/784,551 patent/US6013780A/en not_active Expired - Lifetime
- 1997-09-04 ES ES97940771T patent/ES2212127T3/es not_active Expired - Lifetime
- 1997-09-04 AU AU42471/97A patent/AU737898B2/en not_active Ceased
- 1997-09-04 EA EA199900262A patent/EA004646B1/ru not_active IP Right Cessation
- 1997-09-04 JP JP10512834A patent/JP2001500728A/ja not_active Ceased
- 1997-09-04 CA CA002265252A patent/CA2265252C/fr not_active Expired - Fee Related
- 1997-09-04 CN CN97199495A patent/CN1236390A/zh active Pending
- 1997-09-04 WO PCT/US1997/015471 patent/WO1998010071A1/fr not_active Application Discontinuation
- 1997-09-04 AT AT97940771T patent/ATE256186T1/de not_active IP Right Cessation
- 1997-09-04 DE DE69726741T patent/DE69726741T2/de not_active Expired - Fee Related
- 1997-09-04 EP EP97940771A patent/EP0925360B1/fr not_active Expired - Lifetime
- 1997-09-04 KR KR1019997001920A patent/KR20000068506A/ko not_active Application Discontinuation
- 1997-09-04 NZ NZ334508A patent/NZ334508A/en unknown
- 1997-09-04 IL IL128727A patent/IL128727A/en not_active IP Right Cessation
-
1998
- 1998-03-11 US US09/037,983 patent/US6583276B1/en not_active Expired - Lifetime
-
1999
- 1999-10-28 US US09/428,909 patent/US6589782B1/en not_active Expired - Lifetime
- 1999-12-17 HK HK99105958A patent/HK1020756A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US6013780A (en) | 2000-01-11 |
CA2265252A1 (fr) | 1998-03-12 |
NZ334508A (en) | 2001-03-30 |
EA199900262A1 (ru) | 1999-10-28 |
AU4247197A (en) | 1998-03-26 |
DE69726741D1 (de) | 2004-01-22 |
US6589782B1 (en) | 2003-07-08 |
IL128727A0 (en) | 2005-11-20 |
JP2001500728A (ja) | 2001-01-23 |
EA004646B1 (ru) | 2004-06-24 |
IL128727A (en) | 2007-06-17 |
CN1236390A (zh) | 1999-11-24 |
ATE256186T1 (de) | 2003-12-15 |
WO1998010071A1 (fr) | 1998-03-12 |
EP0925360A1 (fr) | 1999-06-30 |
CA2265252C (fr) | 2005-04-19 |
KR20000068506A (ko) | 2000-11-25 |
ES2212127T3 (es) | 2004-07-16 |
US6583276B1 (en) | 2003-06-24 |
AU737898B2 (en) | 2001-09-06 |
DE69726741T2 (de) | 2004-09-30 |
EP0925360B1 (fr) | 2003-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL128727A0 (en) | Angiogenic factor and use thereof in treating cardiovascular disease | |
WO1999040197A3 (fr) | Variants du facteur angiogenique de croissance cellulaire endotheliale vasculaire vegf | |
PT749317E (pt) | Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade | |
MXPA02002384A (es) | Polipeptidos similares al factor de crecimiento de fibroblastos. | |
DE69531332D1 (de) | Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert | |
Chiba et al. | Transplanted bone marrow stromal cells promote axonal regeneration and improve motor function in a rat spinal cord injury model | |
DE69937294D1 (de) | Von cyclophilin b abstammende tumorantigen-peptide | |
JP2011140495A (ja) | Dna結合タンパク質の使用 | |
KR950700995A (ko) | 조절 신호인 지방체(oil-body) 단백질 시스-요소(cis-element)(OIL-BODY PROTEIN CIS-ELEMENTS AS REGULATORY SIGNALS) | |
ATE294236T1 (de) | Promotor der tie rezeptor protein kinase | |
FR2805821B1 (fr) | Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires | |
ATE88500T1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
ATE433461T1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
Wei et al. | Strategy for improving cell-mediated vascularized soft tissue formation in a hydrogen peroxide-triggered chemically-crosslinked hydrogel | |
DE50009365D1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
EA200000270A1 (ru) | КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
DE60140559D1 (de) | 32144, eine humane fettsäureamid-hydrolase und deren verwendungen | |
CA2441535A1 (fr) | Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport | |
ATE470716T1 (de) | 18480 humane proteinkinasemoleküle und ihre verwendungen | |
DE60002603D1 (de) | Phosphor-enthaltende dendrimere als transfektionsagente | |
AU1318797A (en) | Peptides and uses thereof for therapy of celiac diseases | |
ATE355385T1 (de) | Herstellung von rekombinanten adenoviren und von adenovirus-genbanken | |
ATE265526T1 (de) | Genetisch veränderte fibroblasten und ihre verwendung | |
IL150045A0 (en) | Compositions and methods for detecting stress-inducible proteins | |
Velleman | AN ANALYSIS OF AVIAN CARTILAGE LOW BUOYANT DENSITY PROTEOGLYCANS AND CARTILAGE MATRIX PROTEIN. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20070904 |